Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06141317
Other study ID # 1
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 23, 2023
Est. completion date November 1, 2024

Study information

Verified date November 2023
Source ClusterXStem-Costa Rica
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of allogenic pluripotent stem cells isolated from adipose tissue (PASCs) in patients with Parkinson's Disease.


Description:

Pluripotent Adipose-Derived Stem Cells (PASCs) will be delivered intravenously at a dosage of 25 million PASCs/patient to Parkinson's Disease patients for three infusions each spaced 3 months apart (0, 3, and 6 months). Safety and efficacy of PASC treatment will be monitored over 0, 1, 3, 6, and 12 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date November 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Men =18 years of age or women =45 years of age 2. Written informed consent 3. Receiving drug treatment for diagnosis of mild to moderate Parkinson's Disease 4. Modified Hoehn and Yahr stage 1, 2, or 3 5. Diagnosed with Parkinson's Disease for more than 5 years 6. Stable treatment regimen that has not been modified in the 90 days prior to the start of the study 7. No expected addition of symptomatic therapy for at least one year after the start of the study 8. Women of reproductive age must use contraceptive treatment Exclusion Criteria: 1. Drug-induced Parkinsonism 2. Parkinsonism associated with stroke, progressive supranuclear palsy, Lewy body disease, corticobasal degeneration, or multiple system atrophy 3. Major psychiatric comorbidity that prevents ensuring study follow-up 4. History of alcohol or drug use 5. History of brain surgery for Parkinson's Disease 6. Serious complications deemed inappropriate by Principal Investigator 7. Diagnosis of advanced-stage medical conditions (chronic liver injury with Child-Pugh B or higher, chronic obstructive pulmonary disease with Gold C or higher, or heart failure with ejection fraction <35%) 8. Use of cytostatic drugs 9. Patients with life expectancy < 6 months 10. Diabetes mellitus with poor metabolic control (HbA1c > 8%) 11. Active infectious disease requiring medical treatment 12. Use of systemic steroids or immunosuppressive drugs 13. Patients positive for Hepatitis B antigen, Hepatitis C antibody, or HIV antibody 14. Fertile, pregnant, possibly pregnant, or lactating women 15. History of active mesenchymopathies 16. Active malignancy or diagnosis of malignancy in the last 5 years 17. Abnormal laboratory values, including: - AST >1.5 times Upper Limit of Normal (ULN) (Normal Range: 8 to 48 Units/L) - ALT >1.5 times ULN (Normal Range: 7 to 55 Units/L) - Bilirubin >1.5 times ULN (Normal Range: 0.2 to 1.2 mg/dL) - Creatinine >1.5 times ULN (Normal Range: 0.5 to 1.30 mg/dL) - Hematocrit significantly outside normal range (36% to 54%) - Lymphocytes significantly outside normal range (103 to 4.8 x 103 lymphocytes/µL) - Monocytes significantly outside normal range (200 to 800 lymphocytes/µL) - Neutrophils significantly outside normal range (2.5 x 103 to 7 x 103 lymphocytes/µL) - Erythrocytes significantly outside normal range (4.7 x 106 to 6.1 x 106 lymphocytes/µL) - Platelets significantly outside normal range (150 x 103 to 450 x 103 lymphocytes/µL)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
PASC transplantation (25 million PASCs/patient)
3 doses of 25 million PASCs implantation via peripheral vein (Day 0, 3 months, 6 months)
Control
0.9% saline solution via peripheral vein (Day 0, 3 months, 6 months)

Locations

Country Name City State
Costa Rica Clínica NeuroFT San José
Costa Rica Hospital Clínica Católica San José

Sponsors (3)

Lead Sponsor Collaborator
ClusterXStem-Costa Rica Universidad de Costa Rica, University of California, Los Angeles

Country where clinical trial is conducted

Costa Rica, 

References & Publications (6)

Fisch SC, Gimeno ML, Phan JD, Simerman AA, Dumesic DA, Perone MJ, Chazenbalk GD. Pluripotent nontumorigenic multilineage differentiating stress enduring cells (Muse cells): a seven-year retrospective. Stem Cell Res Ther. 2017 Oct 18;8(1):227. doi: 10.1186/s13287-017-0674-3. — View Citation

Gimeno ML, Fuertes F, Barcala Tabarrozzi AE, Attorressi AI, Cucchiani R, Corrales L, Oliveira TC, Sogayar MC, Labriola L, Dewey RA, Perone MJ. Pluripotent Nontumorigenic Adipose Tissue-Derived Muse Cells have Immunomodulatory Capacity Mediated by Transforming Growth Factor-beta1. Stem Cells Transl Med. 2017 Jan;6(1):161-173. doi: 10.5966/sctm.2016-0014. Epub 2016 Aug 2. — View Citation

Heneidi S, Simerman AA, Keller E, Singh P, Li X, Dumesic DA, Chazenbalk G. Awakened by cellular stress: isolation and characterization of a novel population of pluripotent stem cells derived from human adipose tissue. PLoS One. 2013 Jun 5;8(6):e64752. doi: 10.1371/journal.pone.0064752. Print 2013. Erratum In: PLoS One. 2013;8(7). doi:10.1371/annotation/190d4d01-a63c-4adc-a123-e519ee40a03e. — View Citation

Leung KL, Chazenbalk GD. Human Pluripotent Nontumorigenic Multilineage Differentiating Stress Enduring (Muse) Cells Isolated from Adipose Tissue: A New Paradigm in Regenerative Medicine and Cell Therapy. In Scientific Principles of Adipose Stem Cells, edited by: L Kokai, K Marra, JP Rubin, Editorial Elsevier, Chapter 6, 91-108, 1st Edition, 2021, https://doi.org/10.1016/B978-0-12-819376-1.00004-4

Simerman AA, Phan JD, Dumesic DA, Chazenbalk GD. Muse Cells: Nontumorigenic Pluripotent Stem Cells Present in Adult Tissues-A Paradigm Shift in Tissue Regeneration and Evolution. Stem Cells Int. 2016;2016:1463258. doi: 10.1155/2016/1463258. Epub 2016 Dec 14. — View Citation

Yamashita T, Kushida Y, Abe K, Dezawa M. Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases. Cells. 2021 Apr 20;10(4):961. doi: 10.3390/cells10040961. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score The MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a widely used research tool to quantify the clinical characteristics of PD in adults. This scale assesses various aspects of Parkinson's disease, including motor and non-motor experiences of daily life and motor complications. This test will take approximately 30 minutes, assessing the impact of the disease in 4 different domains distributed in 65 items, of which 48 are scored from 0 to 4 and seven with dichotomous answers of "yes" or "no". The global range of the MDS-UPDRS will be from 0 to 260 points, the higher the score, the greater the disease involvement. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Quality of life as assessed by the 39-item Parkinson's disease Questionnaire (PDQ-39) The 39-item Parkinson's disease Questionnaire (PDQ-39) is the most widely test used to assess specific quality of life questionnaire for Parkinson's disease, and it has been validated and cross-culturally translated. The questionnaire consists of 39 questions to be completed by the patient, that assesses the frequency in which patients with PD experience difficulties in 8 dimensions of functionality and well-being: mobility, activities of daily living, emotional well- being, attention and memory, social support, depression, cognition, communication and social relationships. Items can be transformed on a linear scale from 0 to 100, the higher the score reflects a lower quality of life. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Speech voice sound and duration Since most people with Parkinson's disease (PD) have voice and speech disorders that result in harmful effects on communication and quality of life; the measurement of the pressure level and sound duration will be executed using the Samson Go Mic and the software used for the Lee Silverman Voice Treatment Therapy (LSVT LOUD). Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Dynamic balance and movement during translational motion and single-limb stance in seconds as assessed by the Mini Balance Evaluation Systems Test (mini BESTest) The Mini Balance Evaluation Systems Test (mini BESTest) has proven to be a reliable and valid measurement tool for patients with PD. It is aimed to measure dynamic balance and associated movement during translational motion. The test consists of 14 items, with a maximum score of 28 points, with a higher test result, the greater the patient's functionality 35 . The test has high inter-rater reliability (ICC = 0.92) and high test-retest reliability (ICC = 0.92) for PD patients. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Balance as assessed by the The Five-times Sit-to-stand Test The Five-times sit-to-stand Test is a tool that quantifies the ability of patients suffering from diseases associated with balance problems, as in the case of PD, to perform transitional motions. In addition, it has been used as a measure of lower limb strength. The test has excellent inter-rater reliability and high test-retest reliability, as well as assessing for the risk of falls in patients with PD. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Mobility and fall risk as assessed by the Timed "Up & Go" test The Timed "Up & Go" test consists of observing and timing the patient as he gets up from an armchair, walking for 3 meters, turns, returns and sits down again. The results of this test correlates well with the logarithmic transformation scores on the Berg Balance Scale, gait speed and the Barthel Index of AVD (Activities of Daily Living), and can predict the patient's ability to walk alone safely. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Balance and postural stability as assessed by the Clinical test of Sensory Interaction & Balance Test (CTSIB), stability limits, and unipodal balance test Computerized posturography using a force platform system provides objective and quantitative evaluations of deficiencies in postural control. The participants of the present study will be subjected to two tests of balance and postural stability using the HUMAC®43 brand force platform system. Three tests will be performed: CTSIB test (Clinical test of Sensory Interaction & Balance), the stability limits, and the unipodal balance test. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Tremor and handwriting Alterations in the kinematics of handwriting are among the recently proposed biomarkers of PD. Recent studies have suggested the potential of handwriting analysis for both early diagnosis and assessment of disease progression. In the present study, the patients will be subjected to 5 tests, at 5 different times of the study using the MovAlyzeR® software in conjunction with the WACOM ONE tablet, to measure the speed, amplitude, fluidity and tremor of the movements of the upper extremities. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Grip strength The decrease in grip strength is a predictor of adverse outcomes in older adults and will be determined using a Jamar brand digital dynamometer to measure the grip strength of the patients participating in each assessment. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Primary Dynamic balance in the bipedal as measured by the 360 degree turn test This test measures dynamic balance in the bipedal. In this test, the number of steps and the time that take the patient to make a complete 360-degree turn will be measured. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Secondary Adverse events upon clinical examination Study participants will be examined for clinical signs of adverse events. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
Secondary Optimal number of doses of 2.5 x 10^7 PASCs for therapeutic response The optimal number of doses of PASCs for therapeutic response will be measured. Day 0, 1 Month, 3 Months, 6 Months, 12 Months
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A